Detection and Potential Value of Circulating Tumor DNA in Triple-Negative Breast Cancer
LI Wei;LI Wen-jie;QIAN Cheng;Harbin Medical University Cancer Hospital;
Triple-negative breast cancer(TNBC) is a highly invasive disease with high recurrence rate and low overall survival rate. TNBC has high heterogeneity, and estrogen receptor(ER), progesterone receptor(PR) and human epidermal growth factor receptor 2(Her-2) are all negative, which determine the poor clinical prognosis. Circulating tumor DNA(ctDNA) as a new biological marker, not only can indicate neoadjuvant curative effect and minimal residual disease, but can detect the early metastatic disease, which guides TNBC individualized treatment, and improves the clinical prognosis. This review briefly shows the detection technology of ctDNA, and highlights the potential value of ctDNA in TNBC.